Vitiligo and Treatment
Clinical Medicine Research
Volume 4, Issue 6, November 2015, Pages: 195-197
Received: Aug. 31, 2015; Accepted: Nov. 9, 2015; Published: Dec. 3, 2015
Views 3780      Downloads 75
Sadije Halimi, Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo
Mybera Ferizi, Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo
Antigona Gerqari, Department of Dermatovenerology, University Clinical Centre of Kosovo, Pristina, Republic of Kosovo
Nita Krasniqi, University of Prishtina, Medical Faculty, Pristina, Republic of Kosovo
Mergita Ferizi, University of Prishtina, Medical Faculty, Pristina, Republic of Kosovo
Article Tools
Follow on us
Background: Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. It mainly affects a younger population and can cause serious cosmetic and social problems. At least three theories about the underlying mechanism of vitiligo have been proposed. Release of a chemical that is toxic to melanocytes is one theory, while another theory says that the melanocytes simply self-destruct. According to the third theory, vitiligo is a type of autoimmune disease. Methods: We performed a prospective study to evaluate the efficacy of the 0.05% clobetasol propionate and 1% pimecrolimus in the treatment of vitiligo. In our study is 25 patients with virtually lesions of vitiligo. Results: Results from this pilot study indicate that topical 1% pimecrolimus is as effective as clobetasol propionate in restoring skin disfiguring due to vitiligo. Discussion: Further studies investigating the safety and efficacy of topical 1% pimecrolimus ointment either as monotherapy or in combination with other therapeutic measures are warranted.
Vitiligo, the Skin Dispigmentation, Progress in Treatment of Vitiligo
To cite this article
Sadije Halimi, Mybera Ferizi, Antigona Gerqari, Nita Krasniqi, Mergita Ferizi, Vitiligo and Treatment, Clinical Medicine Research. Vol. 4, No. 6, 2015, pp. 195-197. doi: 10.11648/j.cmr.20150406.15
Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw Hill, 1999: 949-60.
Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12(6): 618-22.
Luger T. Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 2001; 11(4): 343-7.
Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9(5): 346-51.
Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.
Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3.
Vancoillie G, Lambert J, Nayaert JM. Melanocyte biology and its implications for the clinician. Eur J Dermatol 1999; 9(3): 241-51.
Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003; 11: 163-70.
Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003; 13(5): 455-61.
Ongenae K, Van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14(3): 177-81.
Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631-5.
Geraldez CB, Gutierrez GT. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Ther 1987; 9: 474-82.
Clayton R. A double-blind trial of 0-05lobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977; 96: 71-3.
Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05lobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4.
Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3.
Tanghetti EA. Tacrolimus ointment 0.10roduces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186